Coloplast Statistics
Total Valuation
Coloplast has a market cap or net worth of DKK 113.75 billion. The enterprise value is 134.76 billion.
Important Dates
The last earnings date was Tuesday, November 3, 2026.
| Earnings Date | Nov 3, 2026 |
| Ex-Dividend Date | May 18, 2026 |
Share Statistics
Coloplast has 225.17 million shares outstanding.
| Current Share Class | 207.17M |
| Shares Outstanding | 225.17M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +0.09% |
| Owned by Insiders (%) | 5.25% |
| Owned by Institutions (%) | 35.86% |
| Float | 144.57M |
Valuation Ratios
The trailing PE ratio is 37.04 and the forward PE ratio is 19.99. Coloplast's PEG ratio is 3.51.
| PE Ratio | 37.04 |
| Forward PE | 19.99 |
| PS Ratio | 3.93 |
| PB Ratio | 7.96 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 17.19 |
| P/OCF Ratio | 14.21 |
| PEG Ratio | 3.51 |
Financial Ratio History Enterprise Valuation
The stock's EV/EBITDA ratio is 15.47, with an EV/FCF ratio of 20.36.
| EV / Earnings | 43.85 |
| EV / Sales | 4.66 |
| EV / EBITDA | 15.47 |
| EV / EBIT | 18.10 |
| EV / FCF | 20.36 |
Financial Position
The company has a current ratio of 0.74, with a Debt / Equity ratio of 1.51.
| Current Ratio | 0.74 |
| Quick Ratio | 0.41 |
| Debt / Equity | 1.51 |
| Debt / EBITDA | 2.47 |
| Debt / FCF | 3.25 |
| Interest Coverage | 11.32 |
Financial Efficiency
Return on equity (ROE) is 20.21% and return on invested capital (ROIC) is 16.60%.
| Return on Equity (ROE) | 20.21% |
| Return on Assets (ROA) | 6.50% |
| Return on Invested Capital (ROIC) | 16.60% |
| Return on Capital Employed (ROCE) | 22.70% |
| Weighted Average Cost of Capital (WACC) | 6.59% |
| Revenue Per Employee | 1.68M |
| Profits Per Employee | 177,997 |
| Employee Count | 17,270 |
| Asset Turnover | 0.61 |
| Inventory Turnover | 2.43 |
Taxes
In the past 12 months, Coloplast has paid 775.00 million in taxes.
| Income Tax | 775.00M |
| Effective Tax Rate | 20.14% |
Stock Price Statistics
The stock price has decreased by -13.49% in the last 52 weeks. The beta is 0.57, so Coloplast's price volatility has been lower than the market average.
| Beta (5Y) | 0.57 |
| 52-Week Price Change | -13.49% |
| 50-Day Moving Average | 458.34 |
| 200-Day Moving Average | 435.86 |
| Relative Strength Index (RSI) | 57.61 |
| Average Volume (20 Days) | 438,677 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Coloplast had revenue of DKK 28.94 billion and earned 3.07 billion in profits. Earnings per share was 13.64.
| Revenue | 28.94B |
| Gross Profit | 19.25B |
| Operating Income | 7.45B |
| Pretax Income | 3.85B |
| Net Income | 3.07B |
| EBITDA | 8.42B |
| EBIT | 7.45B |
| Earnings Per Share (EPS) | 13.64 |
Full Income Statement Balance Sheet
The company has 511.00 million in cash and 21.52 billion in debt, with a net cash position of -21.01 billion or -93.29 per share.
| Cash & Cash Equivalents | 511.00M |
| Total Debt | 21.52B |
| Net Cash | -21.01B |
| Net Cash Per Share | -93.29 |
| Equity (Book Value) | 14.29B |
| Book Value Per Share | 63.42 |
| Working Capital | -3.51B |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was 8.01 billion and capital expenditures -1.39 billion, giving a free cash flow of 6.62 billion.
| Operating Cash Flow | 8.01B |
| Capital Expenditures | -1.39B |
| Depreciation & Amortization | 969.00M |
| Net Borrowing | -1.57B |
| Free Cash Flow | 6.62B |
| FCF Per Share | 29.40 |
Full Cash Flow Statement Margins
Gross margin is 66.50%, with operating and profit margins of 25.73% and 10.62%.
| Gross Margin | 66.50% |
| Operating Margin | 25.73% |
| Pretax Margin | 13.30% |
| Profit Margin | 10.62% |
| EBITDA Margin | 29.08% |
| EBIT Margin | 25.73% |
| FCF Margin | 22.87% |
Dividends & Yields
This stock pays an annual dividend of 23.00, which amounts to a dividend yield of 4.55%.
| Dividend Per Share | 23.00 |
| Dividend Yield | 4.55% |
| Dividend Growth (YoY) | 4.55% |
| Years of Dividend Growth | 17 |
| Payout Ratio | 36.63% |
| FCF Payout Ratio | 78.23% |
| Buyback Yield | n/a |
| Shareholder Yield | 4.55% |
| Earnings Yield | 2.70% |
| FCF Yield | 5.82% |
Dividend Details Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | |
| Graham Formula Upside | |
Analyst Forecast
The average price target for Coloplast is 473.81, which is -6.21% lower than the current price. The consensus rating is "Hold".
| Price Target | 473.81 |
| Price Target Difference | -6.21% |
| Analyst Consensus | Hold |
| Analyst Count | 21 |
| Revenue Growth Forecast (3Y) | 6.77% |
| EPS Growth Forecast (3Y) | 5.56% |
Stock Splits
The last stock split was on December 19, 2012. It was a forward split with a ratio of 5.
| Last Split Date | Dec 19, 2012 |
| Split Type | Forward |
| Split Ratio | 5 |
Scores
Coloplast has an Altman Z-Score of 3.56 and a Piotroski F-Score of 6.
| Altman Z-Score | 3.56 |
| Piotroski F-Score | 6 |